<DOC>
	<DOCNO>NCT01941446</DOCNO>
	<brief_summary>This randomize , placebo- positive-controlled ( moxifloxacin ) , 3-period , 3-way crossover thorough QT study , include Screening Period , Treatment Periods ( 1 3 ) , Follow-up Visit . Subjects confine investigational site 4 nights/3 day Period 1 3 nights/2 day Periods 2 3 . There minimum 14 day washout treatment .</brief_summary>
	<brief_title>A Thorough QT/QTc Study Evaluate Effects Intravenous Infusion Eravacycline ( TP-434 ) Cardiac Repolarization</brief_title>
	<detailed_description>Each follow treatment evaluate Day 1 period crossover fashion . The IV eravacycline ( TP-434 ) IV placebo double-blinded . - Treatment A : Eravacycline ( TP-434 ) 1.5 mg/kg administer intravenously 60 minute one placebo oral tablet ; - Treatment B : Placebo ( 0.9 % sodium chloride ) administer intravenously 60 minute one moxifloxacin 400 mg oral tablet ; - Treatment C : Placebo ( 0.9 % sodium chloride ) administer intravenously 60 minute one placebo oral tablet . Subjects randomized treatment sequence accord pre-generated treatment scheme . Subjects receive different treatment 3 period .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Healthy male female subject 18 55 year age ; 2 . Females must surgically sterile ( hysterectomy and/or bilateral oophorectomy ) , postmenopausal 1 year ( folliclestimulating hormone [ FSH ] menopausal range ) , agree use 2 medically accept , effective method birth control ( e.g. , hormonal contraception , include oral , implant/patch , injection , latex condom spermicide , diaphragm intravaginal spermicide , cervical cap spermicide , indwell intrauterine device ) time sign informed consent 2 week FollowUp Visit . One birth control method must barrier method ; 3 . Male subject sexual partner childbearing potential must agree use 2 medically accept , effective method birth control ( e.g. , hormonal contraception , include oral , implant/patch , injection , latex condom spermicide , diaphragm intravaginal spermicide , cervical cap spermicide , indwell intrauterine device ) duration study 90 day Followup Visit . Male subject vasectomy &gt; 6 month prior first dose study drug must agree use 1 medically accept barrier method duration study 90 day Followup Visit ; 4 . Male subject ( include vasectomy &gt; 6 month prior first dose study drug ) whose partner currently pregnant must agree use barrier method ( without spermicide ) duration study 2 week Followup Visit ; 5 . Body mass index 18 kg/m2 33 kg/m2 , inclusive ; 6 . Nonsmokers must quit smoke &gt; 3 month prior Screening Visit ; 7 . Have negative alcohol drug screen ; 8 . Have quantitative urine cotinine screen &lt; 3 ; 9 . Willing able confine investigational site require protocol ; 10 . Able comprehend willing provide write informed consent accordance institutional regulatory guideline . 1 . Evidence clinically significant hematologic , renal , endocrine , pulmonary , cardiac , gastrointestinal , hepatic , psychiatric , neurologic , allergic disease ( include multiple clinically significant drug allergy ) , cancer , condition , opinion Investigator , might significantly interfere absorption , distribution , metabolism , excretion study drug , interfere integrity electrophysiologic data , place subject unacceptable risk participant study ; 2 . A personal family history long QT syndrome , Torsades de pointes , complex ventricular arrhythmia family history sudden death ; 3 . Mean QTcF interval &gt; 450 msec screen ECG , perform triplicate . The mean QTcF tracing use Investigator ; 4 . Cardiac conduction abnormality denote follow Screening Visit : evidence seconddegree ( Mobitz type II ) thirddegree atrioventricular block , evidence ventricular preexcitation , complete leave bundle branch block , right bundle branch block , intraventricular conduction delay QRS duration &gt; 120 msec , atrial fibrillation , presence cardiac pacemaker ; PR interval &gt; 220 msec &lt; 120 msec ; heart rate &lt; 45 bpm &gt; 90 bpm ; clinicallysignificant ECG abnormality ( measure mean value triplicate ECGs ) ; 5 . Use hormone replacement therapy ; 6 . Any major surgical procedure within 3 month prior first dose study drug ; 7 . Gastrointestinal disorder surgical procedure could interfere significantly absorption orally administer drug ; 8 . Use another investigational drug device within 30 day prior receive eravacycline ( TP434 ) , within least 5 halflives previous investigational drug , whichever longer ; 9 . History malignancy ( basal cell squamous cell skin cancer , situ carcinoma cervix , situ prostate cancer ) ; 10 . History presence hypertension ( define systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 90 mmHg ) . If subject 's blood pressure outside acceptable range Screening Visit , subject may retested within 24 hour discretion Investigator ; 11 . Known allergy moxifloxacin , quinolone tetracycline antibiotic , related compound history multiple adverse drug allergy origin ; 12 . Inadequate venous access ; 13 . Obvious clinical sign symptom liver disease , acute chronic active hepatitis , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 upper limit normal ( ULN ) . An abnormal ALT AST test may repeat ; 14 . Total bilirubin &gt; 1.5 ULN elevate direct bilirubin . An abnormal total direct bilirubin test may repeat ; 15 . Serum potassium , magnesium , calcium level outside laboratory 's reference range ; 16 . History alcoholism drug abuse within 2 year prior dose ; 17 . Typical weekly alcohol consumption 14 alcoholic drink . One drink define 1 glass beer ( approximately 10 oz 12 oz ) 1 ( 12 oz ) beer , 1 glass wine ( approximately 4 oz 5 oz ) , 1 glass distil spirit ( hard liquor ) contain 1 oz liquor ( 1 oz liquid approximately 30 mL ) ; 18 . Alcohol consumption within 48 hour prior dose ; 19 . Use tobacco , nicotine , nicotinereplacement product within 3 month prior first dose study drug last study visit ; 20 . Unwillingness refrain caffeine xanthinecontaining beverage , include coffee tea , well grapefruit juice , Seville oranges , chocolate within 24 hour prior dose ; 21 . History human immunodeficiency virus ( HIV ) hepatitis C virus positive test screen HIV antibody , hepatitis C antibody , hepatitis B surface antigen ; 22 . Cumulative blood donation &gt; 500 mL within 2 month prior Screening Visit ; 23 . Use prescription nonprescription medication , include vitamin herbal medication , within 7 day , 5 halflives ( know ) , whichever longer , prior dose 3 period within 24 hour dose period . The use acetaminophen , naproxen , ibuprofen permit except within 24 hour prior dose ; 24 . Use prescription nonprescription medication may cause QT prolongation within 14 day , 5 half life , whichever longer , prior dose Period 1 24 hour follow dose Period 3 ; 25 . Any known exposure prescription non prescription medication substance , paint solvent pesticide , know induce inhibit drug metabolize enzyme transport system enzymes , within 30 day 5 halflives , whichever longer , prior dose Period 1 24 hour follow dose Period 3 , exception hormonal contraception ; 26 . Unwillingness abstain strenuous exercise ( e.g. , heavy lifting , weight training , calisthenics , aerobics ) least 48 hour prior admission investigational site ; 27 . Investigational site personnel directly affiliate study ; 28 . Poor mental function reason expect subject difficulty comply requirement study judgment Investigator ; 29 . Failure comply protocol requirement whose participation study would unsuitable subject , determined Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>